<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04653168</url>
  </required_header>
  <id_info>
    <org_study_id>17745</org_study_id>
    <secondary_id>I7P-MC-DSAE</secondary_id>
    <nct_id>NCT04653168</nct_id>
  </id_info>
  <brief_title>A Study of LY3041658 in Healthy Participants</brief_title>
  <official_title>A Single Dose, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Injections of LY3041658 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and tolerability of LY3041658 in&#xD;
      healthy participants. The study will measure how the body absorbs, breaks down and gets rid&#xD;
      of LY3041658.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 7, 2020</start_date>
  <completion_date type="Actual">May 28, 2021</completion_date>
  <primary_completion_date type="Actual">May 28, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With incidence and severity of Injection Site Reaction (ISR)</measure>
    <time_frame>Baseline up to Day 15</time_frame>
    <description>Number of Participants With incidence and severity of ISR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scale (VAS) Score for Injection Site Pain</measure>
    <time_frame>Baseline up to Day 1</time_frame>
    <description>VAS Score for Injection Site Pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3041658</measure>
    <time_frame>Predose up to day 85 postdose</time_frame>
    <description>PK: Cmax of LY3041658</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve (AUC) from time 0 to infinity of LY3041658</measure>
    <time_frame>Predose up to day 85 postdose</time_frame>
    <description>PK: AUC(0-inf) of LY3041658</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3041658 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3041658 administered by subcutaneous (SC) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3041658 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3041658 administered by SC injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3041658</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3041658 High Dose</arm_group_label>
    <arm_group_label>LY3041658 Low Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants who are overtly healthy as determined by medical evaluation including&#xD;
             medical history, physical examination, laboratory tests, vital signs, and ECG.&#xD;
&#xD;
          -  Contraceptive use by men or women should be consistent with local regulations&#xD;
             regarding the methods of contraception for those participating in clinical studies.&#xD;
&#xD;
          -  Have Body mass index (BMI) within the range 18.5 - 35.0 kilograms per square meter&#xD;
             (kg/m2) (inclusive).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a significant cardiovascular, respiratory, hepatic, renal, gastrointestinal,&#xD;
             endocrine, hematological, immune, neurological, dermatological, or psychiatric&#xD;
             disorder capable of significantly altering the absorption, metabolism, or elimination&#xD;
             of drugs; constituting a risk when taking the Study intervention or interfering with&#xD;
             the interpretation of data.&#xD;
&#xD;
          -  Have self-perceived dullness or loss of sensation on either side of their abdomen.&#xD;
&#xD;
          -  Have any condition that could affect pain perception from an injection.&#xD;
&#xD;
          -  Have excessive tattoos or scars over the abdomen, or other factors (eg, rash,&#xD;
             excessive folds of skin) that, in the investigator's opinion, would interfere with&#xD;
             injection site assessments.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lilly Centre for Clinical Pharmacology</name>
      <address>
        <city>Singapore</city>
        <zip>138623</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>June 15, 2021</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

